IO-TKI Findings in nccRCC from KEYNOTE-B61
Following the 2024 ASCO Annual Meeting, Martin H. Voss, MD, discusses long-term follow-up data from the phase 2 KEYNOTE-B61 trial investigating pembrolizumab plus lenvatinib in the first-line treatment of advanced non–clear cell RCC.
EP: 1.Overview of Advanced Non-Clear Cell Renal Cell Carcinoma
EP: 2.Current Treatment Options for Non-Clear Cell Renal Cell Carcinoma
EP: 3.IO-TKI Findings in nccRCC from KEYNOTE-B61
EP: 4.Duration of Therapy and Dosing Strategies in RCC
EP: 5.AE Management With IO-TKI and IO-IO in RCC
EP: 6.Multidisciplinary Strategies for Treating RCC
EP: 7.Meeting Unmet Needs for Patients With RCC
Video content above is prompted by the following question(s):
- Please discuss long term follow-up data from the phase 2 KEYNOTE-B61 trial investigating pembrolizumab + lenvatinib in the first-line treatment of advanced non-clear cell renal cell carcinoma.
Promising Results from Phase 1/2 Trial of NKT2152 for Advanced Kidney Cancer
September 20th 2024NKT2152, a novel oral HIF-2α inhibitor, showed promising results in treating advanced clear cell renal cell carcinoma, with an objective response rate of 20% in all-comers and 26.3% in the dose-escalation population.
Read More
Enhancing Precision in Immunotherapy: CD8 PET-Avidity in RCC
March 1st 2024In this episode of Emerging Experts, Peter Zang, MD, highlights research on baseline CD8 lymph node avidity with 89-Zr-crefmirlimab for the treatment of patients with metastatic renal cell carcinoma and response to immunotherapy.
Listen
Beyond the First-Line: Economides on Advancing Therapies in RCC
February 1st 2024In our 4th episode of Emerging Experts, Minas P. Economides, MD, unveils the challenges and opportunities for renal cell carcinoma treatment, focusing on the lack of therapies available in the second-line setting.
Listen
